Novartis CEO: No on megadeals, yes on medium-sized buyouts


Novartis ($NVS) CEO Joe Jimenez isn't reluctant to rule out megadeals in positioning the giant pharma for the future. But the right kind of "medium-sized" deals, all the rage these days in the biopharma industry, would be fine. The acquisition strategy, though, will have to be tailored to continue the company's dividend support plan. Story

Filed Under